NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; National Cancer Policy Forum. The Drug Development Paradigm in Oncology: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2017 Jul 24.
The Drug Development Paradigm in Oncology: Proceedings of a Workshop.
Show details- ALK
amplastic lymphoma kinase
- ASCO
American Society of Clinical Oncology
- BATTLE-1
Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination
- CAP
College of American Pathologists
- CDER
Center for Drug Evaluation and Research
- CDK
cyclin-dependent kinases
- CLIA
Clinical Laboratory Improvement Amendments of 1988
- CMS
Centers for Medicare & Medicaid Services
- CT
computed tomography
- CY
cyclophosphamide
- DOE
Department of Energy
- DSMB
data and safety monitoring board
- EGFR
epidermal growth factor receptor
- EHR
electronic health record
- EMA
European Medicines Agency
- ER
estrogen receptor
- FDA
Food and Drug Administration
- FNIH
Foundation for the National Institutes of Health
- HDAC
histone deacetylase
- HER2
human epidermal growth factor receptor 2
- HIPAA
Health Insurance Portability and Accountability Act
- IND
investigational new drug
- IRB
Institutional Review Board
- I-SPY TRIAL
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis
- Lung-MAP
Lung Cancer Master Protocol
- MRI
magnetic resonance imaging
- NCI
National Cancer Institute
- NCI-MATCH
National Cancer Institute-Molecular Analysis for Therapy Choice
- NDA
New Drug Application
- NGS
next-generation sequencing
- OCE
Oncology Center of Excellence
- OHOP
Office of Hematology and Oncology Products
- ORR
overall response rate
- OS
overall survival
- PD-1
programmed death-1
- PD-L1
programmed death-ligand 1
- PERCIST
PET Response Criteria in Solid Tumors
- PET
positron emission tomography
- PFS
progression-free survival
- POC
proof of concept
- PRECIS
Pragmatic-Explanatory Continuum Indicator Summary
- RECIST
Response Evaluation Criteria in Solid Tumors
- START
South Texas Accelerated Research Therapeutics
- TAPUR
Targeted Agent Profiling Utilization Registry Study
- Acronyms and Abbreviations - The Drug Development Paradigm in OncologyAcronyms and Abbreviations - The Drug Development Paradigm in Oncology
- Homo sapiens CD200 molecule (CD200), transcript variant 4, mRNAHomo sapiens CD200 molecule (CD200), transcript variant 4, mRNAgi|974005378|ref|NM_001318828.1|Nucleotide
Your browsing activity is empty.
Activity recording is turned off.
See more...